A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Korde N et al. Haematologica. 2014 Mar 21. [Epub ahead of print]. Sotatercept in patients with osteolytic lesions of multiple myeloma. Abdulkadyrov KM et al. Br J Haematol. 2014 Mar 21. doi: 10.1111/bjh.12835. [Epub ahead of print]. Evolution of carfilzomib dose and…
Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation.
Nooka AK et al. Biol Blood Marrow Transplant. 2014 Mar 6. pii: S1083-8791(14)00148-7. doi: 10.1016/j.bbmt.2014.02.025. [Epub ahead of print].
Plasma Exchange for Kidney Disease: What Is the Best Evidence?
Hildebrand AM et al. Adv Chronic Kidney Dis. 2014 Mar;21(2):217-227. doi: 10.1053/j.ackd.2014.01.008.
Rapid Progression of Anemia Related to Tumor-lysis Syndrome Associated with Bortezomib Treatment in Myeloma Patients. Suzuki K et al. Jpn J Clin Oncol. 2014 Mar 23. [Epub ahead of print]. Prediction of presence of kidney disease in a general patient population undergoing intravenous iodinated contrast enhanced computed tomography. Moos SI et al. Eur Radiol. 2014…
Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation.Fouquet G et al. J Cancer. 2014 Mar 11;5(3):248-52. doi: 10.7150/jca.8541. eCollection 2014Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.Mark TM et al. Leuk Lymphoma. 2014 Mar 25. [Epub ahead of…
The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. van de Donk NW et al. Haematologica. 2014 Mar 21. [Epub ahead of print]. A case of CD138-/CD19+/CD4+ IgD plasma cell leukemia. Sorigue M et al. Cytometry B Clin Cytom. 2014 Mar 22. doi: 10.1002/cytob.21173.…
The Pharmacokinetics and Pharmacodynamics of Denosumab in Patients with Advanced Solid Tumours and Bone Metastases: A Systematic Review. Sohn W et al. Br J Clin Pharmacol. 2014 Feb 18. doi: 10.1111/bcp.12355. [Epub ahead of print]. Efficacy of cryotherapy associated with laser therapy for decreasing severity of melphalan-induced oral mucositis during hematological stem-cell transplantation: a prospective…
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Dimopoulos MA et al. Leukemia. 2014 Feb 5. doi: 10.1038/leu.2014.60. [Epub ahead of print]. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Engelhardt M et al. Haematologica. 2014 Feb;99(2):232-42. doi: 10.3324/haematol.2013.099358.…
PET/CT studies of multiple myeloma using 18 F-FDG and 18 F-NaF: comparison of distribution patterns and tracers’ pharmacokinetics. Sachpekidis C et al. Eur J Nucl Med Mol Imaging. 2014 Feb 22. [Epub ahead of print]. Inter-laboratory comparison of Beta-2 microglobulin and albumin methods: impact of assay variation on multiple myeloma staging. Fedele PL et al. Pathology. 2014…
Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. Siegel DS et al. Blood Cancer J. 2014 Feb 21;4:e182. doi: 10.1038/bcj.2014.1. Daratumumab granted breakthrough drug status. Laubach JP et al. Expert Opin Investig Drugs. 2014 Feb 20. [Epub ahead of print]. Anti-CD40-mediated cancer immunotherapy: an update of recent and…
Novel afucosylated anti-B cell maturation antigen-monomethyl auristatin F antibody-drug conjugate (GSK2857916) induces potent and selective anti-multiple myeloma activity. Tai YT et al. Blood. 2014 Feb 25. [Epub ahead of print]. Bone marrow mast cell density correlates with serum levels of VEGF and CXC chemokines ENA-78 and GRO-α in multiple myeloma. Pappa CA et al. Tumour…